Evidence map›Paper›PMID 34364201›Full record

ArticleThe International journal on drug policy2021

Cannabis sales increases during COVID-19: Findings from Alaska, Colorado, Oregon, and Washington.

Gillian L Schauer, Julia A Dilley, Douglas R Roehler, Thomas J Sheehy, Jessica R Filley, Sara Cooley Broschart, Kristin M Holland, Grant T Baldwin, Amy K Holmes-Chavez, Brooke E Hoots

Abstract read
In one paragraph

Article in The International journal on drug policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gillian L SchauerGuest Researcher to: Division of Overdose Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway, N.E., Atlanta, GA 30341, United States; Addictions, Drug & Alcohol Institute, University of Washington, Seattle, WA, United States. Electronic address: gschauer@cdc.gov.
Julia A DilleyMultnomah County Health Department and Oregon Health Authority, Portland, OR, United States.
Douglas R RoehlerDivision of Overdose Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Thomas J SheehyAnalytics & Research, Oregon Liquor Control Commission, Milwaukie, OR, United States.
Jessica R FilleyOffice of Substance Misuse and Addiction Prevention, Alaska Department of Health & Social Services, Anchorage, AK, United States.
Sara Cooley BroschartPublic Health Education, Washington State Liquor and Cannabis Board, Olympia, WA, United States.
Kristin M HollandDivision of Overdose Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Grant T BaldwinDivision of Overdose Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Amy K Holmes-ChavezDivision of Overdose Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Brooke E HootsDivision of Overdose Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States.

Funding

Marijuana Legalization: Assessing the Impact of Local Regulatory PoliciesR01DA039293 · NIDA · MULTNOMAH COUNTY HEALTH DEPARTMENT · PI DILLEY, JULIA ANN · 2015 to 2024
$3.6M
NIDA NIH HHS R01 DA039293
6 · The paper itself

Abstract

BACKGROUND AND

aimsFollowing emergency declarations related to COVID-19 in the United States, many states issued stay-at-home orders and designated essential business categories. Most states allowed medical and/or non-medical adult-use cannabis retailers to remain open. This study assesses changes in cannabis sales across Alaska, Colorado, Oregon, and Washington before and during the pandemic.

methodsPre-tax sales data from cannabis marketplaces in four states were analyzed to identify trends from January 2018-December 2020. Mean monthly sales and relative percent change in mean monthly sales were compared by state from April-December (coinciding with the pandemic) in 2018, 2019, and 2020. Differences were assessed using the nonparametric Mann-Whitney-U test.

resultsMean monthly cannabis sales in all four states were higher during the pandemic period in 2020 compared to the same period in 2019. Sales reached a three-year peak in Washington in May 2020 and in Alaska, Colorado, and Oregon in July 2020. From April-December, the percent change in mean monthly sales from 2019 to 2020 was significantly higher than 2018-2019 in all four states, though Alaska saw similar increases between 2018-2019 and 2019-2020.

conclusionTo date, cannabis sales in Alaska, Colorado, Oregon, and Washington have increased more during the COVID-19 pandemic than in the previous two years. In light of these increases, data monitoring by states and CDC is warranted to understand how patterns of use are changing, which populations are demonstrating changes in use, and how such changes may affect substance use and related public health outcomes.

Indexed as

CannabisCOVID-19AdultAlaskaColoradoHumansOregonPandemicsSARS-CoV-2United StatesWashingtonCannabisCOVID-19Marijuana

Identifiers

PMID34364201
PMCPMC9759692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.